In initial phase I studies, alpelisib monotherapy demonstrated promising clinical activity; however, subsequent data revealed that PI3K inhibition enhances oestrogen signalling in HR+ breast cancer, limiting the overall effectiveness of these compounds [106,107,108]. Here, PIK3CD is linked to breast carcinoma.